Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan.
Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.
Cancer Gene Ther. 2021 Sep;28(9):895-910. doi: 10.1038/s41417-020-00248-7. Epub 2020 Oct 27.
Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine. A variety of microfluidic approaches can provide several functions in processes such as immunologic, genomic, and/or transcriptomic analysis with the aim of improving the efficacy and coverage of immunotherapy, particularly immune checkpoint blockade (ICB). To achieve this requires researchers to overcome the challenges in the current state of the technology. This review looks into the advancements in microfluidic technologies applied to researches on immune checkpoint blockade treatment and its potential shift from proof-of-principle stage to clinical application.
近年来，微流控技术的进步使研究人员能够研究对免疫检查点治疗的敏感性，以确定患者对特定抗体治疗的反应。该技术的利用有助于抗体的发现和个性化药物的设计。各种微流控方法可以在免疫、基因组和/或转录组分析等过程中提供多种功能，旨在提高免疫疗法的疗效和覆盖范围，特别是免疫检查点阻断（ICB）。要实现这一目标，研究人员需要克服当前技术状态下的挑战。这篇综述探讨了应用于免疫检查点阻断治疗研究的微流控技术的进展及其从原理验证阶段向临床应用的潜在转变。
